Why the study?
Does inhibition of thromboxane synthesis or action improve cardiopulmonary abnormalities following experimental pulmonary embolism in dogs?
Population
23 dogs subjected to experimental pulmonary embolism induced with autologous clot (0.5 g/kg or 0.75 g/kg)
Comparison
Pretreatment with imidazole, indomethacin… vs Untreated embolized controls
Design
Preclinical
Follow-up
up to 4 hours
Authors
Loading...
Thromboxane inhibition may mitigate embolism-induced cardiopulmonary changes in dogs; leaves open translation to human therapy.
Does inhibition of thromboxane synthesis or action improve cardiopulmonary abnormalities following experimental pulmonary embolism in dogs?
Thromboxane A2 mediates several cardiopulmonary abnormalities induced by pulmonary embolism, and its inhibition or antagonism can mitigate these effects in a canine model.
Utsunomiya et al. (1982) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: